Where can I get a private Mounjaro prescription?
There are three main routes to a private Mounjaro prescription in the UK, each with different levels of clinical support.
The first is a weight-management programme such as Second Nature, which combines Mounjaro with registered dietitian support and habit-change coaching. This follows the multidisciplinary support model NICE recommends alongside the medication.3
The second is an online pharmacy that provides medication via a brief medical questionnaire and limited ongoing support, and is regulated by the MHRA.
The third is a private GP clinic offering face-to-face consultations and traditional medical monitoring.
The private eligibility criteria are based on the MHRA licence for Mounjaro:
- BMI of 30 or higher, or 27 or higher with at least one weight-related health condition
- Aged 18 to 75
- No contraindications (reasons not to prescribe the medication) listed in the Mounjaro Summary of Product Characteristics
- Commitment to lifestyle changes alongside the medication
The contraindications listed in the Mounjaro SmPC include:5
- Pregnancy, breastfeeding, or trying to conceive
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
- History of pancreatitis
- Severe gastrointestinal disease, including gastroparesis
- Severe kidney problems (eGFR less than 30 ml/min/1.73m²)
The prescription process for most providers starts with an online health questionnaire reviewed by a GMC-registered prescriber, followed by an ID check to comply with MHRA regulations.
How much does a private Mounjaro prescription cost?
Private Mounjaro prices increased significantly after 1 September 2025, when Eli Lilly raised the UK list price by up to 170%.4
The 12.5 mg and 15 mg pre-filled pens jumped from £122 to £330 per month at list price.4
Most providers passed these increases on to private patients during late 2025. Pricing across the UK private market in May 2026 typically falls in the following ranges.
| Dose |
Typical UK private price per month (May 2026) |
| 2.5 mg (starter) |
£140 to £170 |
| 5 mg |
£170 to £230 |
| 7.5 mg |
£200 to £260 |
| 10 mg |
£220 to £290 |
| 12.5 mg and 15 mg |
£250 to £360 |
Some providers price the medication on its own with a separate fee for clinical or coaching support. Others include support in the monthly price.
For a full provider-by-provider breakdown, see our guide to Mounjaro costs in the UK.
Second Nature’s programme combines medication, GMC-registered prescriber oversight, and registered dietitian coaching in a single monthly price, with discounts available for the first month at any dose.
NICE doesn’t set a maximum duration for Mounjaro.3 In practice, most people stay on the medication for 12 to 24 months, with the decision to continue reviewed every 6 months.
NICE recommends continuing only if at least 5% of the starting body weight has been lost at the 6-month review.3
Is there a waiting list for Mounjaro prescriptions?
Private providers don’t currently operate waiting lists. Most can take you from application to delivery within 7 to 14 days if you meet the eligibility criteria.
The typical private timeline is:
- Initial consultation or health questionnaire review: 1 to 5 working days
- Prescription processing: 2 to 3 working days
- Delivery: 1 to 5 working days
The NHS pathway is much slower and depends heavily on which Integrated Care Board you live in.
The general route involves an initial GP appointment, referral to a specialist weight management service, completion of a tier 3 weight management programme, and then an assessment for tirzepatide if you meet the cohort criteria.1
NHS England’s interim commissioning guidance describes a phased rollout, with the eligibility criteria broadening across three cohorts between June 2025 and 2027.1
Supply and availability
The UK supply of Mounjaro KwikPens has remained stable throughout 2026, following the manufacturing capacity issues that affected the higher doses in 2024.
The single-dose vial presentation isn’t currently available, but the KwikPen is the standard format for almost all UK private prescriptions.
Three factors could still affect future supply:
- Expansion of NHS prescribing through the QOF GP contract, which increases overall UK demand
- Global manufacturing capacity at Eli Lilly’s production sites
- Further regulatory or pricing changes from the MHRA or Eli Lilly
When choosing a provider, ask about their contingency plans for shortages and their communication protocol if your dose isn’t available, because interruptions in treatment can affect your weight loss and may increase side effects when you restart.
Choosing the right provider
The level of support that comes with the medication has a measurable effect on results.
Richards et al. (2025), a retrospective service evaluation of Second Nature’s GLP-1-supported programme published in JMIR Formative Research, reported an average weight loss of 19.1% at 12 months among 1,990 adults living with obesity.6 77.7% of participants achieved at least 10% weight loss.6
For comparison, the STEP 1 trial of semaglutide reported an average weight loss of 14.9% at 68 weeks among adults with overweight or obesity, with weekly behavioural counselling but without structured habit-change coaching.7
| Support element |
Programme with coaching |
Medication-only provider |
| Medical screening |
GMC-registered prescriber, full clinical history reviewed |
Basic eligibility check |
| Nutritional support |
Registered dietitian access, usually 5 days a week |
Generic information sheets |
| Habit-change support |
Behavioural coaches and peer groups |
Minimal or none |
| Side effect management |
Proactive coaching and dose adjustment |
Reactive support if you ask |
| Coming off the medication |
Structured tapering and habit-maintenance plan |
Limited or none |
| Safety monitoring |
Regular reviews and progress tracking |
Basic medical questionnaires |
The General Medical Council’s remote prescribing guidance requires all UK providers to carry out an appropriate clinical assessment before prescribing, arrange adequate monitoring, and ensure continuity of care. Checking that a provider meets these standards is part of choosing safely.
Second Nature has worked with the NHS since 2017, combining Mounjaro and Wegovy with structured habit-change coaching and registered-dietitian support.
Take our 3-minute eligibility quiz, and a clinician will review your answers.
Mounjaro vs Wegovy
Both medications are MHRA-approved for weight management and prescribed as a once-a-week injection.
At their licensed top doses, Mounjaro 15 mg produced an average weight loss of 22.5% in SURMOUNT-1 and Wegovy 7.2 mg produced 20.7% in STEP UP, a difference of roughly 2 percentage points.
| Measure |
Mounjaro (tirzepatide) |
Wegovy (semaglutide) |
| Average weight loss at top dose |
22.5% at 15 mg over 72 weeks (SURMOUNT-1)2 |
20.7% at 7.2 mg over 72 weeks (STEP UP)7 |
| Proportion achieving 25% or more weight loss |
36% at 15 mg (SURMOUNT-1)2 |
33% at 7.2 mg (STEP UP)7 |
| How it works |
Mimics two hormones (GLP-1 and GIP) |
Mimics one hormone (GLP-1) |
| Top licensed dose |
15 mg once a week |
7.2 mg once a week (since January 2026) |
| NHS access (May 2026) |
Cohort 1 only until 23 June 2026; broader cohort 2 from that date1 |
Specialist weight management services only |
| Most common side effects |
Nausea, constipation, diarrhoea |
Nausea, constipation, diarrhoea |
Mounjaro mimics two appetite hormones (GLP-1 and GIP), whereas Wegovy mimics only GLP-1.
The dual-hormone action is the likely reason average weight loss with Mounjaro 15 mg was 1 to 2 percentage points higher than with Wegovy 7.2 mg in the published trials.
In the earlier trials of Wegovy 2.4 mg, which was the licensed top dose until January 2026, the difference in average weight loss was 7 to 8 percentage points.
Wegovy 7.2 mg replaced 2.4 mg as the licensed top dose in January 2026, based on the STEP UP trial.7
Most UK private providers now prescribe up to 7.2 mg. Some older articles and price lists still reference 2.4 mg as the maintenance dose.
Individual response varies. Some people respond better to one medication than the other, regardless of the trial averages.
NHS access in 2026
NHS England is rolling out Mounjaro for obesity in three cohorts under NICE Technology Appraisal TA1026 and the NICE funding variation.1,3
Cohort 1, which began in June 2025, covers adults with:
- BMI of 40 or higher (37.5 or higher for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds)
- At least four of five qualifying conditions: type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea, dyslipidaemia
Cohort 2 starts on 23 June 2026, broadening eligibility to adults with:
- BMI of 35 or higher (32.5 or higher with ethnic adjustment)
- At least four of five qualifying conditions
Cohort 3 is expected in March 2027 and will broaden the criteria further.1
From 1 April 2026, prescribing Mounjaro for obesity falls under the 2026/27 GP contract through new QOF indicators.1 GP practices aren’t mandated to prescribe it, so access varies by practice and by Integrated Care Board.
If your GP practice doesn’t currently prescribe Mounjaro, your options are either a referral to a specialist weight management service or a private prescription.
Our guide to Mounjaro on the NHS covers the NHS pathway and what to ask your GP about at your appointment.
Prescription renewal process
Private Mounjaro prescriptions are reviewed and renewed at regular intervals in accordance with GMC and MHRA prescribing guidance.
| Timeframe |
Typical review |
| Monthly |
Weight update, side effect check, brief health questionnaire |
| Every 3 months |
Fuller health review, progress check, dose decision |
| Every 6 months |
Full medication review against the NICE 5% weight loss continuation criterion3 |
NICE guidance recommends continuing Mounjaro only if you’ve lost at least 5% of your starting body weight at the 6-month review.3
The level of monitoring varies between providers.
Programme-style providers usually include integrated monitoring and clinician support. Medication-only providers may need you to arrange blood tests or weight tracking separately.
Frequently asked questions
How quickly can I get Mounjaro privately in the UK?
Most private providers move from application to delivery within 7 to 14 days, comprising 1 to 2 days for the online assessment, 1 to 3 days for prescriber review, and 2 to 5 days for delivery.
Do I need a GP referral for a private Mounjaro prescription?
No. Private providers don’t require a GP referral.
GMC guidance recommends that the prescriber inform your NHS GP (with your consent) so your wider medical record is up to date.
What happens during a private Mounjaro consultation?
A private consultation typically involves a detailed health questionnaire, a review of current medications and previous weight loss attempts, a discussion of side effects and what to expect, an explanation of monitoring, and an ID check.
Can I switch between Mounjaro and Wegovy?
Yes. Switching between Mounjaro and Wegovy is medically possible and sometimes recommended if you aren’t responding well or are experiencing side effects with one of them.
Most prescribers recommend a 7-day washout period when moving between the two, and a fresh dose-titration plan on the new medication.
Your prescriber should adjust the dose and timing based on your individual history. See our guide to switching Mounjaro providers for a list of questions to ask the new clinician.
How long can I stay on Mounjaro?
NICE doesn’t set a maximum duration.3 Most clinicians prescribe Mounjaro for 12 to 24 months, with reviews every 6 months to assess ongoing benefit.
Long-term safety data for tirzepatide now extends to around 3 years.
Will more people qualify for Mounjaro on the NHS soon?
Yes. Cohort 2 begins on 23 June 2026, expanding NHS primary care eligibility to adults with a BMI of 35 or above with four qualifying conditions.1
Cohort 3 is planned for March 2027. Access still varies by GP practice and Integrated Care Board.
What are the eligibility criteria for a private Mounjaro prescription?
Private criteria follow the MHRA licence: a BMI of 30 or above, or 27 or above with at least one weight-related health condition, aged 18 to 75, and no contraindications listed in the Mounjaro Summary of Product Characteristics.
What side effects should I expect with Mounjaro?
The most common side effects are nausea, constipation, and diarrhoea.
These typically settle within 4 to 8 weeks as your body adjusts to the medication and are more noticeable in the first week after each dose increase.
Why did Mounjaro prices increase in 2025?
Eli Lilly raised the UK list price of Mounjaro by up to 170% from 1 September 2025, bringing UK pricing closer to other European markets.4
The increase mainly affected private patients, because NHS pricing is set under a separate agreement.4
Take home message
Private Mounjaro prescriptions are available across the UK from regulated online pharmacies, weight-management programmes, and private GP clinics, with most people moving from application to first injection within 1 to 2 weeks.
NHS access has widened in 2026, with primary care prescribing now in the GP contract and a broader cohort 2 starting on 23 June 2026.
Implementation varies across ICBs and GP practices, so private prescribing remains the main route for most people who meet the MHRA criteria.
Prices rose sharply in late 2025 after Eli Lilly’s price increase, with most private providers now charging between £140 and £360 a month, depending on the dose and the level of clinical and coaching support included.
The research suggests that you’re more likely to avoid weight regain when Mounjaro is combined with structured habit-change support than when prescribed on its own.6
Second Nature has worked with the NHS since 2017 as the lead digital provider for the UK’s two largest NHS weight-loss programmes.
Our Mounjaro programme combines the medication with registered dietitian support and a structured habit-change approach, achieving an average weight loss of 19.1% at 12 months in the published service evaluation.6
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
